Medtech’s haves and have-nots
Medtronic’s quarterly results yesterday might presage a recovery, and some groups are in dire need of one.
A beautiful autumn for Covid-19 test makers
Though orthopaedics companies have begun to recover from the second quarter’s horrors, it is clear that the third quarter belongs to the diagnostics specialists.
Corporate investing plays an ever bigger role in medtech
The newest player in corporate financing, Intuitive, intends to deploy its fund with surgical precision.
Medtechs that book the most sales per employee face the greatest losses
Welcome to the calm before the Covid-19 storm.
Orthopaedics companies’ nightmare quarter
The Covid-19 pandemic has scythed vast sums from joint makers’ Q2 sales. But Medtronic’s summer earnings were better than those for its spring quarter.
Avatera Medical becomes the newest robotic surgery group in Europe
The German start-up must navigate the hazards that have felled other surgical robot developers while simultaneously dealing with a more crowded market.
Another robot deal for J&J shows up lack of Verb results
Johnson & Johnson is going in hard on robotics, but its first big move here has still not paid off.
